文献速递炎症性肠病

乌司奴单抗治疗122例难治性克罗恩病的长期疗效与安全性:多中心经验

Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience.
PubMed 文献 · Aliment Pharmacol Ther · 2018-01-08

该回顾性多中心队列研究纳入2011年3月至2014年12月开始皮下乌司奴单抗治疗且第一年出现临床反应的88例抗TNF难治性克罗恩病患者,随访至2016年11月。中位用药时间26.6个月,47例(54%)维持临床反应继续用药,38例(43%)停药。无失败持续率12个月78%、24个月66%、36个月55%,未识别预测因素,观察到1例严重不良事件(肛管腺癌)。

要点

  • 抗TNF难治性克罗恩病患者中,乌司奴单抗无失败持续率12个月78%、24个月66%、36个月55%。
  • 88例第一年临床反应者中47例(54%)长期维持临床反应继续用药。
  • 内镜评估者中82%出现内镜反应,39%达到黏膜愈合。

核心结论

  • 在难治性克罗恩病长期乌司奴单抗治疗队列中,超过50%的患者继续用药且无失应答、不耐受或手术,安全性良好。

研究设计与样本

  • 回顾性多中心队列研究,纳入2011年3月至2014年12月开始皮下乌司奴单抗且第一年出现临床反应的连续克罗恩病患者,共88例(开始用药者122例中的72%),随访至2016年11月。
  • 主要结局为治疗失败,定义为因失应答、不耐受或需手术而停药。

主要发现

  • 中位用药时间26.6(13.4-34.4)个月;47例(54%)维持临床反应继续用药,38例(43%)停药(32例因失败、5例因缓解、1例因妊娠)。
  • 内镜评估患者中82%出现内镜反应,39%达到黏膜愈合。
  • 无失败持续率12个月78%、24个月66%、36个月55%。
  • 未识别出无失败持续率的预测因素;观察到1例严重不良事件(肛管腺癌)。

关键数值与推荐

  • 临床反应定义为患者医师评估的克罗恩病相关临床症状显著改善并导致继续乌司奴单抗治疗。
  • 治疗失败定义为因失应答、不耐受或需手术而停药。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term outcome of ustekinumab in Crohn's disease (CD) has not been evaluated. AIM: To evaluate the long-term efficacy and safety of ustekinumab and identify the predictive factors of ustekinumab failure-free persistence in a cohort of anti-TNF refractory CD patients. METHODS: We performed a retrospective multicentre cohort study including all consecutive CD patients who began subcutaneous ustekinumab and presented a clinical response (defined as a significant improvement of CD-related clinical symptoms assessed by the patient's physician leading to continued ustekinumab) during the first year of treatment. Primary outcome was treatment failure defined as withdrawal of treatment due to loss of response, intolerance or need for surgery. RESULTS: Eighty-eight of the 122 (72%) CD patients beginning ustekinumab from March 2011 to December 2014, responded to ustekinumab and were followed up until November 2016. Median time on ustekinumab was 26.6 (13.4-34.4) months. Forty-seven patients (54%) continued ustekinumab with a clinical response and 38 (43%) stopped treatment (32 for failure, five for remission and one for pregnancy). Endoscopic response was observed in 82% of patients with endoscopic evaluation and mucosal healing in 39%. Ustekinumab failure-free persistence rates were 78% at 12 months, 66% at 24 months and 55% at 36 months. No predictive factor of ustekinumab failure-free persistence was identified. One severe adverse event was observed (anal adenocarcinoma). CONCLUSION: In this cohort of refractory CD patients receiving long-term ustekinumab therapy, more than 50% of patients continued ustekinumab treatment with no loss of response, intolerance or surgery and with a good safety profile.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Wils P, Bouhnik Y, Michetti P, et al. Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience. Aliment Pharmacol Ther. 2018. PMID: 29315694. doi:10.1111/apt.14487

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。